ProtoKinetix’ AAGP™ Begins 2006 on a Very Positive Note

PROTOKINETIX INC.(PKTX: OTCBB)
Vancouver, British Columbia, January 24, 2006

Dr. John Todd, CEO and President of ProtoKinetix, Inc. (PKTX) states that “With several key projects moving on or ahead of schedule, 2006 starts off for ProtoKinetix very progressively. The Company is extremely positive about the opportunities presently being pursued and that are being presented to it for a number of applications of their proprietary AAGP™ molecules. Meetings with some major corporations this month indicated that the interest level for the commercialization of AAGP™ is high”.

Multinational corporations and institutions are currently examining the anti-aging properties of AAGP™ in the specific areas of:

PKTX has recently upgraded its production capacity to facilitate the rapid demand for AAGP™ molecules. The AAGP™ molecule is proving itself to be the most versatile and powerful agent to dramatically slow down the aging process of cells.

The Company will be announcing the results of AAGP™ as compared to a co-enzyme Q10 analogue in side by side and additive tests later this week. Co-enzyme Q10 is currently being used as an anti-radical in cosmetics and therapeutics, as well as an additive to solutions in organ transplantation.

About ProtoKinetix:

ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company’s first entry into the commercial market place will be the launch of the first synthetic age-arresting glycoprotein (AAGP™). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development in the areas of cell, tissue and organ preservation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,
Dr. John Todd, President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8          

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206